This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
/ / /
/ / /

For healthcare professionals only

You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.

 

This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.

 

This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.

I hereby declare I am a non-US health care professional and that I have read and agreed to the terms mentioned above.

Scroll down

RYBELSUS

RYBELSUS® (semaglutide tablets) is the only GLP-1 RA in a pill, which can deliver HbA1c reduction with the added benefit of weight loss, helping your patients to reduce the risk of long-term complications associated with type 2 diabetes.

As an increasing number of people worldwide are living with diabetes, our device and digital therapeutic innovations have the potential to support diabetes management.

 

Digital Health solutions

Up to 50% of people diagnosed with type 2 diabetes delay starting on insulin1* for more than 2 years2 after it’s recommended.
 
But, with 30 million people with type 2 diabetes worldwide having already taken the positive step to start insulin therapy when it’s needed,3† there are actually 30 million reasons for your patients to say ‘yes’ to insulin.

An early SHIFT in treatment could change lives

When it comes to treating type 2 diabetes, there are more options available than ever before. But a SHIFT in treatment towards early and intensive HbA1c control can reduce the risks associated with type 2 diabetes and help your patients avoid long term complications.4-6
CKD matters in people with T2D

Wegovy® (semaglutide injection 2.4 mg) is the first once-weekly GLP-1 RA* indicated for weight management, helping your patients obtain a 16.7% (17.6 kg) mean weight loss sustained over 2 years.**7,8

 

*GLP-1 RA, glucagon-like peptide-1 receptor agonist.
**At 104 weeks, mean weight loss was 16.7% vs. 0.6% with placebo in the STEP 5 trial8

Connecting medical professionals with useful tools to manage obesity effectively.

Explore a series of articles covering the link between obesity and cardiovascular disease (CVD), the global burden of CVD and the residual CVD risk rising from obesity.9

1.

Rubino A, et al. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK. Diabet Med. 2007;24:1412–1418.

2.

Hosomura N, et al. Decline of insulin therapy and delays in insulin initiation in people with uncontrolled diabetes mellitus. Diabet Med. 2017;34:1599–1602.

3.

Basu S, et al. Estimation of global insulin use for type 2 diabetes, 2018-30: a microsimulation analysis. Lancet Diabetes Endocrinol. 2019;7(S1):25–33 

4.

Dalsgaard N, Vilsbøll T, Knop FK. Effects of glucagon-like peptide receptor agonists on cardiovascular risk factors: A Narrative review of head-to-head comparisons. Diabetes Obes Metab. 2018;20;508-19.

5.

Nauck MA,, Quast DR, Wefers J. et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101-102.

6.

Lovshin JA. Glucagon-like Peptide-1 Receptor Agonists: A class update for treating Type 2 Diabetes. Can J Diabetes. 2017;41:523-35.

7.

Wegovy® [summary of product characteristics]. Bagsværd, Denmark: Novo Nordisk A/S; July 2024.

8.

Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091.

9.

Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. Update From the GBD 2019 Study. J Am Coll Cardiol. 2020 Dec.76(25)2982–3021. Doi: 10.1016/j.jacc.2020.11.010.

*After failure of non-insulin glucose-lowering medications.1
†In a microsimulation of type 2 diabetes burden from 2018 to 2030 across 221 countries, it was estimated that the number of people with type 2 diabetes globally utilising insulin in 2018 was 30,229,435.3

1.

Rubino A, et al. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: a population-based analysis in the UK. Diabet Med. 2007;24:1412–1418.

2.

Hosomura N, et al. Decline of insulin therapy and delays in insulin initiation in people with uncontrolled diabetes mellitus. Diabet Med. 2017;34:1599–1602.

3.

Basu S, et al. Estimation of global insulin use for type 2 diabetes, 2018-30: a microsimulation analysis. Lancet Diabetes Endocrinol. 2019;7(S1):25–33 

4.

Dalsgaard N, Vilsbøll T, Knop FK. Effects of glucagon-like peptide receptor agonists on cardiovascular risk factors: A Narrative review of head-to-head comparisons. Diabetes Obes Metab. 2018;20;508-19.

5.

Nauck MA,, Quast DR, Wefers J. et al. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101-102.

6.

Lovshin JA. Glucagon-like Peptide-1 Receptor Agonists: A class update for treating Type 2 Diabetes. Can J Diabetes. 2017;41:523-35.

9.

Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. Update From the GBD 2019 Study. J Am Coll Cardiol. 2020 Dec.76(25)2982–3021. Doi: 10.1016/j.jacc.2020.11.010.

*After failure of non-insulin glucose-lowering medications.1
†In a microsimulation of type 2 diabetes burden from 2018 to 2030 across 221 countries, it was estimated that the number of people with type 2 diabetes globally utilising insulin in 2018 was 30,229,435.3

FOR HEALTHCARE PROFESSIONALS ONLY

 

The information contained in this site is intended for healthcare professionals only outside of the United States of America. This site is not intended to provide medical advice and/or treatment guidance. Only a physician can determine whether a specific product is correct for a particular patient. This site is not country-specific and therefore may contain information which is not applicable to your country. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional. Any images shown on the page are a mix of models and real patients.

 

HQ24NNG00173, October 2024